Document is current
Any future updates will be listed below
-
Authors
Ichikawa, Takahiro
Hashimoto, Yoshitaka
Okamura, Takuro
Obora, Akihiro
Kojima, Takao
Okada, Hiroshi
Hamaguchi, Masahide
Fukui, Michiaki
- License Information
-
More Information
Article History
Received: 8 October 2024
Accepted: 12 March 2025
First Online: 26 March 2025
Declarations
:
: The protocol for the present research project was approved by Asahi University Hospital Ethics Committee, (approval number:2018-09-01) in accordance with the provisions of the Declaration of Helsinki. Informed consent was obtained from all participants and/or their guardians.
: Not applicable.
: Ichikawa T grants from Abbott Japan Co. Ltd. Hashimoto Y received personal fees from Novo Nordisk Pharma Ltd., Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd., Nippon Boehringer Ingelheim Co., Mitsubishi Tanabe Pharma Corp., Kowa Company, Ltd., Taisho Pharma Co., Eli Lilly Japan K.K. and Daiichi Sankyo Co. Hamaguchi M received grants from AstraZeneca K.K., Ono Pharma Co. Ltd., Kowa Pharma Co. Ltd. Fukui M received grants from Ono Pharma Co. Ltd., Oishi Kenko inc., Yamada Bee Farm, Nippon Boehringer Ingelheim Co. Ltd., Kissei Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corp., Daiichi Sankyo Co. Ltd., Sanofi K.K., Takeda Pharma Co. Ltd., Astellas Pharma Inc., MSD K.K., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Kowa Pharma Co. Ltd., Novo Nordisk Pharma Ltd., Sanwa Kagagu Kenkyusho CO., Ltd., Eli Lilly, Japan, K.K., Taisho Pharma Co., Ltd., Terumo Corp., Tejin Pharma Ltd., Nippon Chemiphar Co., Ltd., Abbott Japan Co. Ltd., and Johnson & Johnson K.K. Medical Co., TERUMO CORPORATION. All authors’ grants were outside the submitted work.
